Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis

References

• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–11. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018;17(12):854–855. doi:10.1038/nrd.2018.210.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–1684. doi:10.1200/JCO.2017.77.0412.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–459. doi:10.1056/NEJMoa1709919.
   PubMed Web of Science ®Google Scholar
• Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018;10(436):eaao5931. doi:10.1126/scitranslmed.aao5931.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064.
   PubMed Web of Science ®Google Scholar
• Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer. 2018;96:17–24. doi:10.1016/j.ejca.2018.03.015.
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Bratke K, Stoll P. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;379:e14. doi:10.1056/NEJMc1808251.
   PubMed Web of Science ®Google Scholar
• Jia L, Zhang Q, Zhang RX. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med. 2018;15(2):116–123. doi:10.20892/j..2095-3941.2017.0086.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324. doi:10.1126/scitranslmed.aad7118.
   Web of Science ®Google Scholar
• Zhang Y, Chen L. Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2(11):1403–1404. doi:10.1001/jamaoncol.2016.2450.
   PubMed Web of Science ®Google Scholar
• Radvanyi L, Pilon-Thomas S, Peng W, Sarnaik A, Mule JJ, Weber J, Hwu P. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer–letter. Clin Cancer Res. 2013;19(19):5541. doi:10.1158/1078-0432.CCR-13-1054.
   PubMed Web of Science ®Google Scholar
• Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14(10):653–666. doi:10.1038/nri3737.
   PubMed Web of Science ®Google Scholar
• Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392–396. doi:10.1038/s41586-019-1456-0.
   PubMed Web of Science ®Google Scholar
• Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018;128(11):4912–4923. doi:10.1172/JCI120612.
   PubMed Web of Science ®Google Scholar
• van de Wall S, Santegoets KCM, van Houtum EJH, Bull C, Adema GJ. Sialoglycans and siglecs can shape the tumor immune microenvironment. Trends Immunol. 2020;41(4):274–285. doi:10.1016/j.it.2020.02.001.
   PubMed Web of Science ®Google Scholar
• Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Démoulins T, Schneider C, Wehrli M, Hunger RE, Baerlocher GM, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 2014;124(4):1810–1820. doi:10.1172/JCI65899.
   PubMed Web of Science ®Google Scholar
• Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014;10(1):69–75. doi:10.1038/nchembio.1388.
   PubMed Web of Science ®Google Scholar
• Angata T, Tabuchi Y, Nakamura K, Nakamura M. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology. 2007;17(8):838–846. doi:10.1093/glycob/cwm049.
   PubMed Web of Science ®Google Scholar
• Hiruma Y, Hirai T, Tsuda E. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation. Biochem Biophys Res Commun. 2011;409(3):424–429. doi:10.1016/j.bbrc.2011.05.015.
   PubMed Web of Science ®Google Scholar
• Ishida-Kitagawa N, Tanaka K, Bao X, Kimura T, Miura T, Kitaoka Y, Hayashi K, Sato M, Maruoka M, Ogawa T, et al. Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12). J Biol Chem. 2012;287(21):17493–17502. doi:10.1074/jbc.M111.324194.
   PubMed Web of Science ®Google Scholar
• Stuible M, Moraitis A, Fortin A, Saragosa S, Kalbakji A, Filion M, Tremblay GB. Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption. J Biol Chem. 2014;289(10):6498–6512. doi:10.1074/jbc.M113.494542.
   PubMed Web of Science ®Google Scholar
• Hiruma Y, Tsuda E, Maeda N, Okada A, Kabasawa N, Miyamoto M, Hattori H, Fukuda C. Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice. Bone. 2013;53(1):87–93. doi:10.1016/j.bone.2012.11.036.
   PubMed Web of Science ®Google Scholar
• Kameda Y, Takahata M, Komatsu M, Mikuni S, Hatakeyama S, Shimizu T, Angata T, Kinjo M, Minami A, Iwasaki N, et al. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12. J Bone Miner Res. 2013;28(12):2463–2475. doi:10.1002/jbmr.1989.
   PubMed Web of Science ®Google Scholar
• Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology. 2013;23(2):178–187. doi:10.1093/glycob/cws139.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656–666. doi:10.1038/s41591-019-0374-x.
   PubMed Web of Science ®Google Scholar
• Xiubao R. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. Cancer Biology & Medicine. 2019;16(2):205. doi:10.20892/j..2095-3941.2018.0141.
   PubMed Web of Science ®Google Scholar
• Cao G, Xiao Z, Yin Z. Normalization cancer immunotherapy: blocking Siglec-15! Signal Transduct Target Ther. 2019;4(1):10. doi:10.1038/s41392-019-0045-x.
   PubMed Web of Science ®Google Scholar
• Poh A. Siglec-15: an attractive immunotherapy target. Cancer Discov. 2020;10:7–8. doi:10.1158/2159-8290.CD-NB2019-136.
   Web of Science ®Google Scholar
• Deng M, Bragelmann J, Schultze JL, Perner S. Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. BMC Bioinformatics. 2016;17(1):72. doi:10.1186/s12859-016-0917-9.
   PubMed Web of Science ®Google Scholar
• Wei L, Jin Z, Yang S, Xu Y, Zhu Y, Ji Y. TCGA-assembler 2: software pipeline for retrieval and processing of TCGA/CPTAC data. Bioinformatics. 2018;34(9):1615–1617. doi:10.1093/bioinformatics/btx812.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data: figure 1. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002.
   PubMed Web of Science ®Google Scholar
• Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets (vol 8, 9227, 2018). Sci Rep-Uk. 2018:8. doi:10.1038/s41598-018-29514-3.
   Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210.
   PubMed Web of Science ®Google Scholar
• Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. doi:10.1038/s41587-019-0114-2.
   PubMed Web of Science ®Google Scholar
• Anastasiadi D, Esteve-Codina A, Piferrer F. Consistent inverse correlation between DNA methylation of the first intron and gene expression across tissues and species. Epigenetics Chromatin. 2018;11(1):37. doi:10.1186/s13072-018-0205-1.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The Immune Landscape of Cancer. Immunity. 2019;51(2):411–412. doi:10.1016/j.immuni.2019.08.004.
   PubMed Web of Science ®Google Scholar
• Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017;117(1):1–7. doi:10.1038/bjc.2017.136.
   PubMed Web of Science ®Google Scholar
• Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):29. doi:10.1186/s13045-020-00862-w.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588. doi:10.1093/annonc/mdz011.
   PubMed Web of Science ®Google Scholar
• Murugesan G, Correia VG, Palma AS, Chai W, Li C, Feizi T, Martin E, Laux B, Franz A, Fuchs K, et al. Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression. Glycobiology. 2020. doi:10.1093/glycob/cwaa048.
   Web of Science ®Google Scholar
• Chang L, Chen Y-J, Fan C-Y, Tang C-J, Chen Y-H, Low P-Y, Ventura A, Lin -C-C, Chen Y-J, Angata T, et al. Identification of siglec ligands using a proximity labeling method. J Proteome Res. 2017;16(10):3929–3941. doi:10.1021/acs.jproteome.7b00625.
   PubMed Web of Science ®Google Scholar
• Briard JG, Jiang H, Moremen KW, Macauley MS, Wu P. Cell-based glycan arrays for probing glycan-glycan binding protein interactions. Nat Commun. 2018;9(1):880. doi:10.1038/s41467-018-03245-5.
   PubMed Web of Science ®Google Scholar
• Jandus P, Boligan KF, Smith DF, de Graauw E, Grimbacher B, Jandus C, Abdelhafez MM, Despont A, Bovin N, Simon D, et al. The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies. Blood. 2019;134(22):1941–1950. doi:10.1182/blood.2019001705.
   PubMed Web of Science ®Google Scholar
• Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56. doi:10.1038/s41586-019-1593-5.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, et al. Aberrant PD-L1 expression through 3 ‘-UTR disruption in multiple cancers. Nature. 2016;534(7607):402. doi:10.1038/nature18294.
   PubMed Web of Science ®Google Scholar
• Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, Rimm DL, Liu Y, Ratner ES, Schwartz PE, et al. Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement. Clinical Cancer Research. 2018;24(14):3282–3291. doi:10.1158/1078-0432.Ccr-17-1805.
   PubMed Web of Science ®Google Scholar
• Gupta S, Cheville JC, Jungbluth AA, Zhang Y, Zhang L, Chen Y-B, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, et al. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathol. 2019;32(9):1344–1358. doi:10.1038/s41379-019-0269-x.
   PubMed Web of Science ®Google Scholar
• Wang YC, Wenzl K, Manske MK, Asmann YW, Sarangi V, Greipp PT, Krull JE, Hartert K, He R, Feldman AL, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J. 2019;9(9). doi:10.1038/s41408-019-0233-5
   Google Scholar
• Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, Fitzpatrick C, McElherne J, MacNabb BW, Orlowski R, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019;133(21):2279–2290. doi:10.1182/blood-2018-10-879015.
   PubMed Web of Science ®Google Scholar
• Imperato S, Mistretta C, Marone, Marone M, Migliaccio I, Pulcinelli I, Faraone Mennella MR. Automodified Poly(ADP-Ribose) polymerase analysis to monitor DNA damage in peripheral lymphocytes of floriculturists occupationally exposed to pesticides. Cells. 2019;8(2). doi:10.3390/cells8020137.
   PubMed Web of Science ®Google Scholar
• Otto JE, Kadoch C. A two-faced mSWI/SNF subunit: dual roles for ARID1A in tumor suppression and oncogenicity in the liver. Cancer Cell. 2017;32(5):542–543. doi:10.1016/j.ccell.2017.10.014.
   PubMed Web of Science ®Google Scholar
• Rankin LC, Arpaia N. Treg cells: A LAGging hand holds the double-edged sword of the IL-23 axis. Immunity. 2018;49(2):201–203. doi:10.1016/j.immuni.2018.08.008.
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhang MH, Zhang Y, Meng HX, Wang Y, Liu YP, Jing J, Hang L, Sun MQ, Zhang Y, et al. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis. Cancer Biol Med. 2018;15(3):290–298. doi:10.20892/j..2095-3941.2018.0047.
   PubMed Web of Science ®Google Scholar
• Kondratova M, Czerwinska U, Sompairac N, Amigorena SD, Soumelis V, Barillot E, Zinovyev A, Kuperstein I. A multiscale signalling network map of innate immune response in cancer reveals cell heterogeneity signatures. Nat Commun. 2019;10(1):4808. doi:10.1038/s41467-019-12270-x.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi:10.1056/NEJMoa1113205.
   PubMed Web of Science ®Google Scholar
• McDonald K-A, Kawaguchi T, Qi Q, Peng X, Asaoka M, Young J, Opyrchal M, Yan L, Patnaik S, Otsuji E, et al. Tumor heterogeneity correlates with less immune response and worse survival in breast cancer patients. Ann Surg Oncol. 2019;26(7):2191–2199. doi:10.1245/s10434-019-07338-3.
   PubMed Web of Science ®Google Scholar
• Pecuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, Laurent-Puig P, Wislez M. Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. Ann Oncol. 2017;28(7):1597–1604. doi:10.1093/annonc/mdx162.
   PubMed Web of Science ®Google Scholar
• Boyd CR, Orr SJ, Spence S, Burrows JF, Elliott J, Carroll HP, Brennan K, Gabhann JN, Coulter WA, Johnston JA, et al. Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J Immunol. 2009;183(12):7703–7709. doi:10.4049/jimmunol.0902780.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Sakuma K, Kawamura YI, Izawa M, Ohmori K, Mitsuki M, Yamaji T, Hashimoto Y, Suzuki A, Saito Y, et al. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and −9. J Immunol. 2012;188(9):4690–4700. doi:10.4049/jimmunol.1100605.
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz H-J. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40–47. doi:10.1016/j.ctrv.2017.11.007.
   PubMed Web of Science ®Google Scholar
• Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca A, Dammacco F. CXCR3-binding chemokines in multiple myeloma. Cancer Lett. 2004;207(2):221–227. doi:10.1016/j.canlet.2003.10.036.
   PubMed Web of Science ®Google Scholar
• Wang B-Q, Zhang C-M, Gao W, Wang X-F, Zhang H-L, Yang P-C. Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. J Cancer Res Clin Oncol. 2011;137(10):1525–1533. doi:10.1007/s00432-011-1010-4.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35. doi:10.1016/j.immuni.2019.12.011.
   PubMed Web of Science ®Google Scholar